Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023;16(2):2660-2671.
doi: 10.1007/s12274-022-5002-2. Epub 2022 Nov 15.

Recent advances of bioresponsive polymeric nanomedicine for cancer therapy

Tu Hong #  1 , Xinyuan Shen #  2 , Madiha Zahra Syeda #  1 , Yang Zhang  2 , Haonan Sheng  2 , Yipeng Zhou  3 , JinMing Xu  4 , Chaojie Zhu  2   5 , Hongjun Li  2   6   5 , Zhen Gu  2   6   7   8   9 , Longguang Tang  1
Affiliations
Review

Recent advances of bioresponsive polymeric nanomedicine for cancer therapy

Tu Hong et al. Nano Res. 2023.

Abstract

A bioresponsive polymeric nanocarrier for drug delivery is able to alter its physical and physicochemical properties in response to a variety of biological signals and pathological changes, and can exert its therapeutic efficacy within a confined space. These nanosystems can optimize the biodistribution and subcellular location of therapeutics by exploiting the differences in biochemical properties between tumors and normal tissues. Moreover, bioresponsive polymer-based nanosystems could be rationally designed as precision therapeutic platforms by optimizing the combination of responsive elements and therapeutic components according to the patient-specific disease type and stage. In this review, recent advances in smart bioresponsive polymeric nanosystems for cancer chemotherapy and immunotherapy will be summarized. We mainly discuss three categories, including acidity-sensitive, redox-responsive, and enzyme-triggered polymeric nanosystems. The important issues regarding clinical translation such as reproducibility, manufacture, and probable toxicity, are also commented.

Keywords: bioresponsive; cancer therapy; drug delivery; immunotherapy; polymer.

PubMed Disclaimer

References

    1. DeBerardinis R J, Lum J J, Hatzivassiliou G, Thompson C B. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11–20. doi: 10.1016/j.cmet.2007.10.002. - DOI - PubMed
    1. Ganesh K, Massague J. Targeting metastatic cancer. Nat. Med. 2021;27:34–44. doi: 10.1038/s41591-020-01195-4. - DOI - PMC - PubMed
    1. Janiszewska M. The microcosmos of intratumor heterogeneity: The space-time of cancer evolution. Oncogene. 2020;39:2031–2039. doi: 10.1038/s41388-019-1127-5. - DOI - PMC - PubMed
    1. Marusyk A, Polyak K. Tumor heterogeneity: Causes and consequences. Biochim. Biophys. Acta Rev. Cancer. 2010;1805:105–117. doi: 10.1016/j.bbcan.2009.11.002. - DOI - PMC - PubMed
    1. Siegel R L, Miller K D, Fuchs H E, Jemal A. Cancer statistics, 2022. CA Cancer J. Clin. 2022;72:7–33. doi: 10.3322/caac.21708. - DOI - PubMed

LinkOut - more resources